Voyager Therapeutics (VYGR) Competitors

Voyager Therapeutics (NASDAQ:VYGR) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.

Which has more risk and volatility, VYGR or OCS?

Voyager Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in VYGR or OCS?

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate VYGR or OCS?

Voyager Therapeutics presently has a consensus price target of $13.97, indicating a potential upside of 283.69%. Oculis has a consensus price target of $30.25, indicating a potential upside of 60.31%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Oculis	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in VYGR or OCS?

Voyager Therapeutics received 368 more outperform votes than Oculis when rated by MarketBeat users. However, 91.67% of users gave Oculis an outperform vote while only 67.97% of users gave Voyager Therapeutics an outperform vote.

Company	Underperform	Outperform
Voyager Therapeutics	Outperform Votes 401 67.97%	Underperform Votes 189 32.03%
Oculis	Outperform Votes 33 91.67%	Underperform Votes 3 8.33%

Does the media favor VYGR or OCS?

In the previous week, Oculis had 5 more articles in the media than Voyager Therapeutics. MarketBeat recorded 6 mentions for Oculis and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.19 beat Oculis' score of 1.02 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is VYGR or OCS more profitable?

Voyager Therapeutics has a net margin of 15.80% compared to Oculis' net margin of -8,043.28%. Voyager Therapeutics' return on equity of 8.33% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	15.80%	8.33%	6.15%
Oculis	-8,043.28%	-71.31%	-56.85%

Which has stronger valuation & earnings, VYGR or OCS?

Voyager Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$80.00M	2.52	$132.33M	-$1.13	-3.22
Oculis	$980K	840.72	-$98.92M	-$2.31	-8.17

Summary

Voyager Therapeutics beats Oculis on 16 of the 19 factors compared between the two stocks.